Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2013, Pages 265-270

  Watz, Henrik ^a   Bock, Daniel ^b   Meyer, Michael ^b   Schierhorn, Katrin ^b   Vollhardt, Karin ^b   Woischwill, Christiane ^b   Pedersen, Frauke ^a   Kirsten, Anne ^a   Beeh, Kai Michael ^c   Meyer Sabellek, Wolfgang ^b   Magnussen, Helgo ^a   Beier, Jutta ^c  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b Revotar Biopharmaceuticals AG   (Germany)

^c Insaf   (Germany)

Author keywords

Airway inflammation; COPD; Pan selectin antagonism

Indexed keywords

BIMOSIAMOSE; GELATINASE B; INTERLEUKIN 8; MYELOPEROXIDASE;

ADULT; ARTICLE; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; LUNG FUNCTION; LYMPHOCYTE COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NEBULIZER; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; RHINOPHARYNGITIS; SIDE EFFECT; SPIROMETRY; SPUTUM; SPUTUM ANALYSIS; THIRST; THORAX PAIN; TREATMENT DURATION;

ADMINISTRATION, INHALATION; AGED; ASTHMA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEXANES; HUMANS; INTERLEUKIN-8; MALE; MANNOSE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SELECTINS;

EID: 84874564716     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.12.003     Document Type: Article

References (36)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2011: http://www.goldcopd.org.
2. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22:672-688.
3. Barnes P.J., Hansel T.T. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004, 364:985-996.
4. Barnes P.J., Stockley R.A. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005, 25:1084-1106.
5. Grootendorst D.C., Gauw S.A., Verhoosel R.M., Sterk P.J., Hospers J.J., Bredenbröker D., et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007, 62:3277-3284.
6. Calverley P.M.A., Rabe K.F., Goehring U.-M., Kristiansen S., Fabbri L.M., Martinez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 2009, 374:685-694.
7. Fabbri L.M., Calverley P.M.A., Izquierdo-Alonso J.L., Bundschuh D.S., Brose M., Martinez F.J., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomized clinical trials. Lancet 2009, 374:695-703.
8. Bock D., Aydt E.M., Kuebler W.M., Wolff G. The role of selectins during lung inflammation and their potential impact for innovative therapeutic strategies. Curr Respir Med Rev 2006, 2:339-354.
9. Hirata T., Furie B.C., Furie B. P-, E-, and L-selectin mediate migration of activated CD8+ T lymphocytes into inflamed skin. J Immunol 2002, 169:4307-4313.
10. Aydt E.M., Bock D., Wolff G. Selectin antagonists and their potential impact for the treatment of inflammatory lung diseases. Progress in respiratory research 2010, vol. 39. New Drugs and Targets for Asthma and COPD, London.
11. Di Stefano A., Maestrelli P., Roggeri A., Tuarto G., Calabro S., Potena A., et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med 1994, 149:803-810.
12. Turato G., Di Stefano A., Maestrelli P., Mapp C.E., Ruggieri M.P., Roggeri A., et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995, 152:1262-1267.
13. Schumacher A., Liebers U., John M., Gerl V., Meyer M., Witt C., et al. P-selectin glycoprotein ligand-1 (PSGL-1) is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2005, 142:370-376.
14. Riise G.C., Larsson S., Löfdal C.G., Andersson B.A. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. Eur Respir J 1994, 7:1673-1677.
15. Ferroni P., Basili S., Martini F., Vieri M., Labbadia G., Cordova C. Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J Investig Med 2000, 48:21-27.
16. Kirsten A., Watz H., Kretschmar G., Pedersen F., Bock D., Meyer-Sabellek W., et al. Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects-a double blind, randomized, placebo-controlled, cross-over clinical trial. Pulm Pharmacol Ther 2011, 24:555-558.
17. Beeh K.M., Beier J., Meyer M., Buhl R., Zahlten R., Wolff G. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther 2005, 19:233-241.
18. Watz H., Bock D., Meyer M., Schierhorn K., Vollhardt K., Woischwill C., et al. Inhaled pan-selectin antagonist Bimosiamose in COPD: a double-blind, randomized, placebo-controlled phase II study. Eur Respir J 2011, 38(Suppl. 55):4492.
19. Meyer M., Jilma B., Zahlten R., Wolff G. Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration. Int J Clin Pharm Ther 2005, 43:463-471.
20. Meyer M., Beyer D., Vollhardt K., Woischwill C., Jilma B., Wolff G. The pharmacokinetics of subcutaneously injected bimosiamose disodium in healthy male volunteers. Biopharm Drug Disp 2007, 28:475-484.
21. Pin I., Gibson P.G., Kolendowicz R., Girgis-Gabardo A., Denburg J.A., Hargreave F.E., et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992, 47:25-29.
22. Holz O., Jörres R.A., Koschyk S., Speckin P., Welker L., Magnussen H. Changes in sputum composition during sputum induction in healthy and asthmatic subjects. Clin Exp Allergy 1998, 28:284-292.
23. Kelly M.M., Keatings V., Leigh R., Peterson C., Shute J., Venge P., et al. Analysis of fluid-phase mediators. Eur Respir J 2002, 20(Suppl. 37):24s-39s.
24. Woolhouse I.S., Bayley D.L., Stockley R.A. Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis. Thorax 2002, 57:667-671.
25. Miller M.R., Crapo R., Hankinson J., Brusasco V., Burgos F., Casaburi R., et al. General considerations for lung function testing. Eur Respir J 2005, 26:153-161.
26. Jones B., Kenward M.G. Design and analysis of cross-over-trials 2003, Chapman & Hall/CRC, Boca Raton, p. 76-90. 2nd ed.
27. Culpitt S.V., Rogers D.F., Shah P., De Matos C., Russell R.E.K., Donnelly L.E. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:24-31.
28. Russell R.E.K., Culpitt S.V., De Matos C., Donnelly L., Smith M., Wiggings J., et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002, 26:602-609.
29. Shapiro S.D. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:S29-S32.
30. Tetley T.D. Macrophages and the pathogenesis of COPD. Chest 2002, 121:156S-159S.
31. Barnes P.J. Alveolar macrophages as orchestrators of COPD. COPD 2004, 1:59-70.
32. Ito K., Ito M., Elliott W.M., Cosio B., Caramori G., Kon O.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005, 352:1967-1976.
33. Beeh K., Beier J., Liebers U., Schumacher A., Meyer M., Bock D., et al. Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD. Eur Respir J 2007, 30(Suppl. 51):3601.
34. Magnussen H., Watz H., Kirsten A., Wang H., Wray H., Samuelsson V., et al. Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial. Pulm Pharmacol Ther 2011, 24:563-570.
35. Dahl R., Titlestad I., Lindqvist A., Wielders P., Wray H., Wang M., et al. Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial. Pulm Pharmacol Ther 2012, 25:169-177.
36. Lomas D.A., Lipson D.A., Miller B.E., Willits L., Keene O., Barnacle H., et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2011, 52:416-424.